Roche has presented new data which shows Gazyva is superior to its established Rixtuxan/Mabthera in treating follicular lymphoma (FL). Rituxan/MabThera is one of Roche's biggest sellers ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

Rituximab, developed in partnership by Roche and Biogen Idec, was the first anti-CD20 monoclonal antibody to be approved for the treatment of non-Hodgkin lymphomas. It works by specifically ...

controlled trial conducted in France that used Roche’s EU-approved rituximab. The study compared the Ritux 3 regimen (EU-approved rituximab product plus short-term corticosteroids [CS]) to CS ...

Roche Holding AG RHHBY announced that the late ... lived longer than those treated with MabThera/Rituxan (rituximab) in combination with GemOx. The study’s secondary endpoints include ...

In January, the Swiss drug manufacturer Roche announced a €190 million ($175 million) investment to manufacture a device that enables the subcutaneous injection of biologics, notably its ...

Japanese drugmaker Kyowa Kirin and Swiss generics and biosimilars giant Sandoz have won approval for the partial change of their rituximab biosimilar for the treatment of refractory nephrotic syndrome ...

6,7 “For patients with DLBCL who relapse after initial therapy, urgent and effective treatment is required to regain disease control,” said Levi Garraway, MD, PhD, Roche’s Chief Medical ...

However, Roche faced a CHF 1bn sales decline from the loss of exclusivity on older products, including cancer therapies Avastin (bevacizumab), Herceptin (trastuzumab), and Rituxan (rituximab).

The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with DLBCL. A similar percentage of patients in each arm experienced treatment-emergent ...

Moreover, because the use of rituximab reduced the neutralization ... Another co-author reported receiving research grants from CSL Vifor, Roche, and GlaxoSmithKline and advisory board ...